Efficacy of RG1-VLP Vaccination against Infections with Genital and Cutaneous Human Papillomaviruses

Licensed human papillomavirus (HPV) vaccines, based on virus-like particles (VLPs) self-assembled from major capsid protein L1, afford type-restricted protection against HPV types 16/18/6/11 (or 16/18 for the bivalent vaccine), which cause 70% of cervical cancers (CxCas) and 90% of genital warts. Ho...

Descripción completa

Detalles Bibliográficos
Autores principales: Schellenbacher, Christina, Kwak, Kihyuck, Fink, Dieter, Shafti-Keramat, Saeed, Huber, Bettina, Jindra, Christoph, Faust, Helena, Dillner, Joakim, Roden, Richard B.S., Kirnbauer, Reinhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3826974/
https://www.ncbi.nlm.nih.gov/pubmed/23752042
http://dx.doi.org/10.1038/jid.2013.253

Ejemplares similares

Ejemplares similares